Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-02

Clinical Trial Update: A Study of AK0529 in Infants Hospitalized With RSV [Phase 1]

View source ↗

Summary

A Phase 1 trial of the RSV therapy AK0529 in infants hospitalized with Respiratory Syncytial Virus infections was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AK0529 (AK0529)

Snippet

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: TERMINATED